Heidelberg Pharma AG/ DE000A11QVV0 /
2020-12-22 12:00:00 AM | Chg. - | Volume | Bid9:02:12 AM | Ask9:02:12 AM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
7.18EUR | - | 48 Turnover: - |
-Bid Size: - | -Ask Size: - | 88.52 mill.EUR | 0.00% | - |
GlobeNewswire
2017-11-16
Antibody Drug Conjugates Market, 2030 - Market is Anticipated to Grow at a CAGR to 19.4%
GlobeNewswire
2007-11-12
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2007-11-12
HEIDELBERG PHARMA AG starts second clinical phase II study with FOSALVUDINE
GlobeNewswire
2007-02-05
Recruitment completed for phase IIa trial with fosfluridine tidoxil in actinic keratosis
GlobeNewswire
2006-10-09
Start of clinical phase II with Fosalvudine for treatment of HIV-infected patients